Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics entities : Aclaris therapeutics, inc. save search
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -2.2%
H: 2.39%
C: 1.34%
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 2.48%
H: 10.48%
C: -3.23%
year update therapeutics financial results
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 14.72%
H: 17.92%
C: 9.43%
business review therapeutics
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Published: 2024-01-10 (Crawled : 12:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -16.41%
H: 6.54%
C: -6.07%
ati-1777 dermatitis trial therapeutics results
Aclaris Therapeutics Provides Corporate Update
Published: 2023-12-19 (Crawled : 21:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -2.78%
H: 0.84%
C: -5.71%
update therapeutics
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Published: 2023-12-05 (Crawled : 21:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 9.49%
H: 6.48%
C: -5.56%
pharma patent license therapeutics agreement
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -85.28%
H: 0.0%
C: -7.87%
ati-450 update trial therapeutics results
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 1.12%
H: 5.06%
C: 0.92%
update therapeutics financial results
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 0.97%
H: 2.65%
C: -7.94%
ati-1777 dermatitis therapeutics study
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Published: 2023-09-20 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -0.27%
H: 0.88%
C: -8.51%
conference global therapeutics
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -5.75%
H: 0.0%
C: -1.46%
ati-2138 positive trial therapeutics results
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: -8.14%
update therapeutics financial results
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
Published: 2023-06-13 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 1.3%
H: 8.34%
C: 1.18%
ati-450 therapeutics study
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
Published: 2023-06-02 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 1.15%
H: 3.64%
C: -0.11%
therapeutics
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-05-08 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -3.79%
H: 1.04%
C: -2.78%
update therapeutics financial results
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
Published: 2023-05-02 (Crawled : 11:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -0.54%
H: 0.98%
C: -2.72%
therapeutics financial results
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Published: 2023-03-27 (Crawled : 12:20) - biospace.com/
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 0.37%
H: 3.02%
C: 1.24%
conference disease therapeutics
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -40.53%
H: 1.84%
C: -6.97%
ati-450 topline therapeutics study
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Published: 2023-02-23 (Crawled : 14:00) - biospace.com/
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 0.39%
H: 2.75%
C: 0.24%
year therapeutics financial update results
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
Published: 2023-02-09 (Crawled : 22:00) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: -0.51%
H: 3.84%
C: 3.63%
biopharma global conference therapeutics
Aclaris Therapeutics Provides 2023 Outlook
Published: 2023-01-06 (Crawled : 12:20) - globenewswire.com
ACRS | $1.215 0.41% 0.41% 1.1M
|
Health Technology
|
| O: 0.72%
H: 8.44%
C: 7.89%
therapeutics
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.